ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Information for professionals for BAQSIMI®:Future Health Pharma GmbH
Complete information for professionalsDDDÄnderungen anzeigenPrint 
Composition.Galenic FormIndication.UsageContra IndicationWarning restrictions.Interactions.Pregnancy
Driving abilityUnwanted effectsOverdoseEffectsPharm.kinetikPreclinicalOther adviceSwissmedic-Nr.
PackagesRegistration ownerLast update of information 
H04AA01 - GlucagonATC-DDD Version 2016. Source: WHO
H - Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins

This group comprises all hormonal preparations for systemic use, except:
- Insulins, see A10.
- Anabolic steroids, see A14.
- Catecholamines, see C01C and R03C.
- Sex hormones, see G03.
- Sex hormones used in treatment of neoplastic diseases, see L02.
- Metreleptin used for treatment of complications of leptin deficiency in patients with generalised lipodystrophy is classified in A16AA.

The DDDs are generally based on the treatment or diagnosis of endocrine disorders.

H04 - Pancreatic Hormones
 
H04A - Glycogenolytic Hormones
 
H04AA - Glycogenolytic Hormones

The pancreas glycogenolytic hormone glucagon is classified in this group.
Diazoxide, which is also used for treatment of hypoglycemia, is classified in C02DA01 and V03AH01.
Insulins are classified in A10A.

The DDD of glucagon is based on single dose treatment of hypoglycemia.

H04AA01 - Glucagon
DoseRoute of administrationNote
 N 
 P 
2025 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home